Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Combined moxibustion/adalimumabin treatment of ankylosing spondylitis, and its influence on related functional indicators

Longfei Han¹, Jianying Zhang² , Hui Liang²

¹Shandong Traditional Chinese Medicine University, Jinan, Shandong, China; ²Traditional Chinese Medicine External Treatment Center of Shandong Provincial Hospital of Traditional Chinese Medicine, Jinan, Shandong, China.

For correspondence:- Jianying Zhang Email: caojingrang184744@163.com Tel:+8613066035253

Accepted: http://dx.doi.org/10.4314/tjpr.v21i3.25 Published: 31 March 2022

Citation: Han L, Zhang J, Liang H. Combined moxibustion/adalimumabin treatment of ankylosing spondylitis, and its influence on related functional indicators. Trop J Pharm Res 2022; 21(3):635-641 doi: 10.4314/tjpr.v21i3.25

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To study the clinical efficacy of the combination of du-moxibustion and adalimumab in the treatment of ankylosing spondylitis, as well as its influence on related functional indicators.

Methods: From 2019 to 2020, 90 ankylosing spondylitis patients treated in Shandong Traditional Chinese Medicine University Hospital were assessed for eligibility and recruited. They were assigned, based on the order of admission, to receive either conventional treatment (control group) or du-moxibustion plus adalimumab (study group). Clinical treatment efficacy, levels of inflammatory indices, and spinal mobility in the two groups were determined and compared. Numerical Rating Scale (NRS) was employed for pain assessment, while Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was used for disease status evaluation. Bath Ankylosing Spondylitis Functional Index (BASFI) was used for assessing functional limitation.

Results: Du-moxibustion plus adalimumab was associated with significantly higher treatment efficacy and lower levels of inflammatory factors when compared to conventional treatment (p < 0.05). Comparable NRS scores before treatment and 2 weeks after treatment were observed in the two groups (p > 0.05). The eligible patients given du-moxibustion plus adalimumab showed lower NRS scores, higher BASDAI scores, and lower BASFI scores versus those receiving conventional treatment (p < 0.001).

Conclusion: Treatment of ankylosing spondylitis patients with the combination of du-moxibustion and adalimumab mitigates symptoms and clinical indicators of the disease and relieves pain in the patients. Therefore, the combined treatment should be subjected to further clinical trials prior to its use in clinical practice.

Keywords: Du-moxibustion, Adalimumab, Ankylosing spondylitis, Numerical rating scale, Inflammatory factors, BASDAI, BASFI